[go: up one dir, main page]

WO2005079774A3 - Management of ophthalmologic disorders, including macular degeneration - Google Patents

Management of ophthalmologic disorders, including macular degeneration Download PDF

Info

Publication number
WO2005079774A3
WO2005079774A3 PCT/US2005/004990 US2005004990W WO2005079774A3 WO 2005079774 A3 WO2005079774 A3 WO 2005079774A3 US 2005004990 W US2005004990 W US 2005004990W WO 2005079774 A3 WO2005079774 A3 WO 2005079774A3
Authority
WO
WIPO (PCT)
Prior art keywords
management
macular degeneration
including macular
ophthalmologic disorders
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/004990
Other languages
French (fr)
Other versions
WO2005079774A2 (en
Inventor
Robert R Rando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2006133300/04A priority Critical patent/RU2006133300A/en
Priority to US10/598,048 priority patent/US20080176952A1/en
Priority to CA002555261A priority patent/CA2555261A1/en
Priority to JP2006554196A priority patent/JP2007525496A/en
Priority to MXPA06008780A priority patent/MXPA06008780A/en
Priority to BRPI0507807-5A priority patent/BRPI0507807A/en
Priority to EP05723179A priority patent/EP1722766A2/en
Priority to AU2005215778A priority patent/AU2005215778B2/en
Application filed by Harvard University filed Critical Harvard University
Priority to US11/199,594 priority patent/US7566808B2/en
Publication of WO2005079774A2 publication Critical patent/WO2005079774A2/en
Publication of WO2005079774A3 publication Critical patent/WO2005079774A3/en
Priority to IL177284A priority patent/IL177284A0/en
Priority to IS8530A priority patent/IS8530A/en
Anticipated expiration legal-status Critical
Priority to NO20064181A priority patent/NO20064181L/en
Priority to US12/347,343 priority patent/US20090227649A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/25—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/45—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/45—Monoamines
    • C07C211/48—N-alkylated amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C07C217/86—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/10—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/28—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/40—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/15—Unsaturated ethers containing only non-aromatic carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/203—Unsaturated compounds containing keto groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/24—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short­circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.
PCT/US2005/004990 2004-02-17 2005-02-17 Management of ophthalmologic disorders, including macular degeneration Ceased WO2005079774A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU2005215778A AU2005215778B2 (en) 2004-02-17 2005-02-17 Management of ophthalmologic disorders, including macular degeneration
US10/598,048 US20080176952A1 (en) 2004-02-17 2005-02-17 Management of Ophthalmologic Disorders, Including Macular Degeneration
CA002555261A CA2555261A1 (en) 2004-02-17 2005-02-17 Management of ophthalmologic disorders, including macular degeneration
JP2006554196A JP2007525496A (en) 2004-02-17 2005-02-17 Management of ophthalmic diseases including macular degeneration
MXPA06008780A MXPA06008780A (en) 2004-02-17 2005-02-17 Management of ophthalmologic disorders, including macular degeneration.
BRPI0507807-5A BRPI0507807A (en) 2004-02-17 2005-02-17 management of eye disorders, including macular degeneration
EP05723179A EP1722766A2 (en) 2004-02-17 2005-02-17 Management of ophthalmologic disorders, including macular degeneration
RU2006133300/04A RU2006133300A (en) 2004-02-17 2005-02-17 OPTALMOLOGICAL DISORDER MANAGEMENT, INCLUDING YELLOW SPOT DEGENERATION
US11/199,594 US7566808B2 (en) 2004-02-17 2005-08-08 Management of ophthalmologic disorders, including macular degeneration
IL177284A IL177284A0 (en) 2004-02-17 2006-08-03 Management of ophthalmologic disorders, including macular degeneration
IS8530A IS8530A (en) 2004-02-17 2006-08-10 Treatment of eye disorders including shrinkage
NO20064181A NO20064181L (en) 2004-02-17 2006-09-15 Treatment of eye disorders, including macular degeneration
US12/347,343 US20090227649A1 (en) 2004-02-17 2008-12-31 Management of Ophthalmologic Disorders, Including Macular Degeneration

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US54545604P 2004-02-17 2004-02-17
US60/545,456 2004-02-17
US56760404P 2004-05-03 2004-05-03
US60/567,604 2004-05-03
US57832404P 2004-06-09 2004-06-09
US60/578,324 2004-06-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/199,594 Continuation-In-Part US7566808B2 (en) 2004-02-17 2005-08-08 Management of ophthalmologic disorders, including macular degeneration

Publications (2)

Publication Number Publication Date
WO2005079774A2 WO2005079774A2 (en) 2005-09-01
WO2005079774A3 true WO2005079774A3 (en) 2006-03-02

Family

ID=34891141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004990 Ceased WO2005079774A2 (en) 2004-02-17 2005-02-17 Management of ophthalmologic disorders, including macular degeneration

Country Status (13)

Country Link
US (1) US20080176952A1 (en)
EP (1) EP1722766A2 (en)
KR (1) KR20060135819A (en)
AU (1) AU2005215778B2 (en)
BR (1) BRPI0507807A (en)
CA (1) CA2555261A1 (en)
IL (1) IL177284A0 (en)
IS (1) IS8530A (en)
MX (1) MXPA06008780A (en)
NO (1) NO20064181L (en)
PL (1) PL380611A1 (en)
RU (1) RU2006133300A (en)
WO (1) WO2005079774A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610772A4 (en) 2003-03-14 2008-06-18 Univ Washington RETINOID SUBSTITUTES AND OSPINE AGONISTS AND METHODS OF USE THEREOF
RU2408578C2 (en) 2004-06-18 2011-01-10 Юниверсити Оф Вашингтон Derivatives of retinal and methods of their application to treat visual impairment
NZ551955A (en) * 2004-06-23 2010-08-27 Revision Therapeutics Inc Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2006033734A2 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
US7432307B2 (en) 2004-11-04 2008-10-07 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation
EP1858499A4 (en) * 2005-02-24 2010-03-03 Univ Washington METHODS OF TREATING RETINAL DEGENERATIVE DISEASE
ES2393768T3 (en) * 2005-05-26 2012-12-27 Neuron Systems, Inc Quinoline derivative for the treatment of retinal diseases
GB2426450A (en) * 2005-06-06 2006-11-29 Sytera Inc Methods and compositions for treating ophthalmic conditions with retinyl derivatives
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
RU2494089C2 (en) 2007-04-20 2013-09-27 Акьюсела Инк. Compounds representing styrene derivatives for treating ophthalmic diseases and disorders
US20100227811A1 (en) * 2007-05-14 2010-09-09 University Of South Florida Farnesylamine derivatives and methods of use
NZ587376A (en) 2008-02-11 2012-06-29 Univ Washington Methods for the treatment and prevention of age-related retinal dysfunction
CA2774168C (en) 2009-09-15 2021-02-23 Ronald Erwin Boch Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
SG10201507819VA (en) 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
EP2648711A2 (en) * 2010-12-06 2013-10-16 ReVision Therapeutics, Inc. Compositions and methods for treating ophthalmic conditions
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
SG11201504859YA (en) 2012-12-20 2015-07-30 Aldeyra Therapeutics Inc Peri-carbinols
RU2676694C9 (en) 2013-01-23 2019-06-25 Альдейра Терапьютикс, Инк. Toxic aldehyde related diseases and treatment
RU2015126015A (en) 2013-01-25 2017-03-03 Альдейра Терапьютикс, Инк. NEW CATCHERS IN THE TREATMENT OF MACULODYSTROPHY
BR112018003250A2 (en) 2015-08-21 2018-09-25 Aldeyra Therapeutics Inc deuterated compounds and uses thereof
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CA3054811A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3630083A4 (en) * 2017-05-23 2021-03-10 The Regents of The University of Michigan DIMETHYL-NONATETRAENYL-TRIMETHYL-CYCLOHEXYL COMPOUNDS AND USES THEREOF
JP7311162B2 (en) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド Treatment of inflammatory disorders
JP2021533154A (en) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド Polymorphic compounds and their use
JP2022530967A (en) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド Polymorphic compounds and their use
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2023526016A (en) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド Pharmaceutical formulations and their uses
US20220380282A1 (en) * 2021-05-17 2022-12-01 P2 Science, Inc. Terpenol ethers
KR102840048B1 (en) * 2022-03-11 2025-07-28 재단법인대구경북과학기술원 Chemogenetically Activatable Palmitoylation Regulatory Protein and Use Thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354594A1 (en) * 2002-04-17 2003-10-22 Cognis Iberia, S.L. Combinations of an extract of a vaccinium type plant and a carotene
WO2004082622A2 (en) * 2003-03-14 2004-09-30 University Of Washington Retinoid replacements and opsin agonists and methods for the use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2654722A (en) * 1950-09-16 1953-10-06 Standard Oil Dev Co Stabilized solid organic compositions containing acyl-p-aminophenols
US3780103A (en) * 1967-03-30 1973-12-18 Ciba Geigy Corp Alkylhydroxybenzylamides
ZA6808345B (en) * 1967-12-22 May & Baker Ltd Benzene derivatives
US4215215A (en) * 1975-08-01 1980-07-29 Hoffmann-La Roche Inc. 9-Phenyl-nonate traene compounds
US4108880A (en) * 1975-11-03 1978-08-22 Johnson & Johnson Esters of retinoic acid
US4310546A (en) * 1978-07-31 1982-01-12 Johnson & Johnson Novel retinoids and their use in preventing carcinogenesis
US4742400A (en) * 1986-02-12 1988-05-03 Ricoh Corporation Digital image processing device for intermediate tone
US4743400A (en) * 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5661138A (en) * 1996-10-03 1997-08-26 Clarion Pharmaceutical, Inc. (o-Acyl-p-N-acylamino-phenyl)-O-phosphoethanolamines
JP3972159B2 (en) * 1998-05-12 2007-09-05 グンゼ株式会社 Film for vapor deposition balloon
EP1259470A4 (en) * 2000-02-07 2005-06-15 Zhenhua Yang A group of anti-cancer compounds with specific structure and their production method
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
NZ551955A (en) 2004-06-23 2010-08-27 Revision Therapeutics Inc Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2006047475A2 (en) * 2004-10-25 2006-05-04 Sytera, Inc. Detection and analysis of ophthalmically-relevant fluorescent molecules
JP4178281B2 (en) * 2004-12-08 2008-11-12 シリオン セラピューティクス， インコーポレイテッド Methods, assays and compositions for treating retinol-related diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354594A1 (en) * 2002-04-17 2003-10-22 Cognis Iberia, S.L. Combinations of an extract of a vaccinium type plant and a carotene
WO2004082622A2 (en) * 2003-03-14 2004-09-30 University Of Washington Retinoid replacements and opsin agonists and methods for the use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 16 November 1984 (1984-11-16), "Methyl 2,4-butanedioate", XP002341530, retrieved from STN Database accession no. RN 1515-75-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 16 November 1984 (1984-11-16), XP002341531, retrieved from STN Database accession no. RN 1515-76-0 *

Also Published As

Publication number Publication date
NO20064181L (en) 2006-11-14
IL177284A0 (en) 2006-12-10
EP1722766A2 (en) 2006-11-22
KR20060135819A (en) 2006-12-29
BRPI0507807A (en) 2007-07-31
US20080176952A1 (en) 2008-07-24
PL380611A1 (en) 2007-02-19
AU2005215778A1 (en) 2005-09-01
WO2005079774A2 (en) 2005-09-01
CA2555261A1 (en) 2005-09-01
AU2005215778B2 (en) 2009-03-12
IS8530A (en) 2006-09-15
MXPA06008780A (en) 2007-02-16
RU2006133300A (en) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2005079774A3 (en) Management of ophthalmologic disorders, including macular degeneration
WO2007019503A3 (en) Management of ophthalmologic disorders, including macular degeneration
WO2008130803A3 (en) Pulmonary delivery of spherical insulin microparticles
WO2007027761A3 (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
WO2008107149A3 (en) Pharmaceutical form with impeded abuse
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
MX336861B (en) Abuse resistant drug formulation.
WO2005020972A3 (en) Combination therapy for the treatment of ocular neovascular disorders
HK1212240A1 (en) Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
WO2005069865A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2006071274A3 (en) Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
WO2006055603A3 (en) Injectable nanoparticulate olanzapine formulations
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
JP2007536277A5 (en)
WO2006068921A3 (en) Device for ophthalmic drug delivery
ZA200808465B (en) Pharmaceutical formulations:salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
WO2010058926A3 (en) Pharmaceutical composition containing ginger extract or shogaol
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2009118726A3 (en) Oral combination of vitamins
WO2006085115A3 (en) Therapeutic uses of tomato extracts
WO2009116076A3 (en) Ophthalmic preparation containing a pyridinol derivative
WO2008128191A3 (en) Oral cephalotaxine dosage forms
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11199594

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 11199594

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2555261

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 177284

Country of ref document: IL

Ref document number: PA/a/2006/008780

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006554196

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 549269

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005215778

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4962/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005215778

Country of ref document: AU

Date of ref document: 20050217

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005215778

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200607713

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005723179

Country of ref document: EP

Ref document number: 1020067019039

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006133300

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580011513.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005723179

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067019039

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0507807

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10598048

Country of ref document: US